Recent Advances in Skin Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: 17 October 2024 | Viewed by 2357
Special Issue Editor
Special Issue Information
Dear Colleagues,
While most cutaneous squamous cell carcinomas (cSCCs) are low-risk tumors and treated definitively with surgery, a subset of cSCC is associated with metastasis and death. In recent years, the introduction of the Brigham and Women’s Hospital tumor staging system and the updated American Joint Committee on Cancer guidelines have been instrumental in predicting the risk of poor outcomes from cSCC. Gene expression profile testing of cSCC can provide additional prognostic information to guide the implementation of surveillance strategies and adjuvant therapies. The use of immunotherapy, specifically the PD1 inhibitor cemiplimab, has been a game changer in the treatment of locally advanced or metastatic cSCC.
In this Special Issue, we will highlight major advances in the staging, prognostication, and treatment of cSCC.
Dr. Syril Keena T. Que
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cutaneous squamous cell carcinoma
- staging
- surgical treatment
- immunotherapy
- cemiplimab
- adjuvant radiation
- gene expression profile
- Brigham and Women’s Hospital tumor staging system
- American Joint Committee on Cancer staging system
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.